Interviews

Stephen M. Ansell, MD, PhD, discusses the key takeaways from his session at 2024 Society of Hematologic Oncology Annual Meeting in the advanced stage Hodgkin lymphoma space.

Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress.

Sarah Sammons, MD, provides an overview of the DESTINY-Breast03 trial.

Meredith McKean, MD, discusses a longer-term follow-up study investigating fianlimab and cemiplimab immunotherapy in advanced melanoma.

Shirish M. Gadgeel, MD, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology Congress.

Kenneth Shain, MD, PhD, discusses why he recommends most patients with relapsed/refractory multiple myeloma be referred for evaluation to receive chimeric antigen receptor T-cell therapy.

Naomi Dempsey, MD, discussed developments in the HER2-positive breast cancer space, including personalized approaches, less toxic treatments, promising trial results, and more.

Alessandra Ferrajoli, MD, discusses the session she was a part of at the 2024 Society of Hematologic Oncology Annual Meeting.

Anil Parwani, MD, PhD, addresses potential biases or limitations in the artificial intelligence algorithm used at his institution.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.

Partow Kebriaei, MD, discusses transplant in acute lymphoblastic leukemia.

Sangeetha Venugopal, MD, MS, discusses how measurable residual disease is used during the course of treatment of AML.

Jeff Sharman, MD, discusses the clinical implications for oncologists based on data from the ELEVATE-TN trial.

Sangeetha Venugopal, MD, MS, discusses the dynamic landscape of molecular targets in acute myeloid leukemia.

Christina Henson, MD, discusses how new guidelines for head and neck cancer imaging could change dynamics for physicians and patients.

Claire Saxton, MBA, discusses findings from a study looking at social toxicity in acute myeloid leukemia.

Anil Parwani, MD, PhD, discusses the use of artificial intelligence technology to enhance cancer diagnostics and treatment.

Julie Vose, MD, discusses the exciting developments across lymphomas.

Anil Parwani, MD, PhD, discusses how the use of artificial intelligence technology can be integrated into the current workflow of pathologists.

Mayra Shanley, PhD, discussed background and future directions for evaluating IL-21 natural killer cells for the treatment of glioblastoma.

Elizabeth Franzmann, MD, discusses findings of a study exploring a novel method of testing recurrence of head and neck cancer.

Christopher Moertel, MD, discussed findings from the phase 2 ReNeu trial of mirdametinib in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.

Ira Zackon, MD, explains how clinicians can ensure clinical trial patient populations are more inclusive and minorities are better represented.

In an interview, Anil Parwani, MD, PhD, discussed how artificial intelligence can be used in medical education and training, as well as its role in personalized medicine.

Jeff Sharman, MD, discusses findings from the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab for the treatment of patients with treatment-naive chronic lymphocytic leukemia.

Anil Parwani, MD, PhD, professor of pathology at The Ohio State University Wexner Medical Center, discusses the artificial intelligence (AI) technology that is currently being used at his institution.

Habte Yimer, MD, discussed the findings from the phase 3 ALPINE trial and explored how these results are shaping clinical decisions in chronic lymphocytic leukemia treatment.